• Change from list-based to risk-based approach
• Risk classification – need to reclassify all devices
• Relationship between IVDR risk requirements, ISO 14971 and ISO 13485
• Establishing appropriate relationships between risk management, clinical evaluation, and postmarket activities and reports
• Challenges and strategies for new products, in-production and legacy products